Ensysce Biosciences
Develops opioid-safety prodrugs and a neuroplastogenic pain candidate.
Something off on this page? Send us feedback.
Profile
Develops opioid pain candidates based on trypsin-activated and dose-limiting prodrug chemistry, alongside CY200 for complex regional pain syndrome. Current revenue is federal grant reimbursement, and all candidates remain unapproved.
Develops PF614, a trypsin-activated oxycodone prodrug for severe pain, and PF614-MPAR, which adds nafamostat to limit further activation after excessive oral dosing. The acquired CY200 program is a clinical-stage neuroplastogenic therapy for complex regional pain syndrome.
Operates from La Jolla, California, while using CROs and contract manufacturers for clinical development and supply. Federal research grants, rather than product sales, provide current revenue; approvals or collaborations could support future product, upfront, milestone and royalty revenue.
Pursues dose-limiting oral-delivery chemistry alongside neuroplastogenic pain research, but has no approved candidate. Its progress depends on clinical evidence, FDA review, grant funding, outsourced manufacturing, controlled-substance supply, and Nasdaq continued-listing compliance.
Company facts
Key statistics
Analysts
No analyst consensus on record.
Earnings
EPSReportedEstimate
RevenueReportedEstimate
Financials
Balance sheet, Jun 30, 2026Cash & short-term investments $676.7K · Total debt $196.8K · Total assets $3.0M · Shareholders' equity −$781.7K
- Revenue
- $1.2M
- Operating income
- −$2.6M
- Net income
- −$2.6M
Dividends
No dividends on record.
Ownership
| Insiders2 holders · as of Aug 18, 2026 | 6.21% | 1.21M shares | |
| Otherremainder | 93.79% | 18.25M shares |
19.46M company shares as of Sep 1, 2026 · holders as of their latest filing
Two share counts disagree (19.46M in the company's Sep 1, 2026 report, 15.37M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Bob G. Gower1Insiderdirector | 6.20% | 1.21M | 13Dfiled Aug 18, 2026 ↗ |
William H. Chang2Insiderdirector, 10 percent owner | 0.00% | 721 | 13Dfiled Jul 12, 2021 ↗ |
AQR Capital Management, LLCInstitution | —2.20% of class, as filed | — | 13D/Gfiled Feb 15, 2019 ↗ |
BMO Capital Markets Corp.Institution | —6.23% of class, as filed | — | 13Gfiled Feb 14, 2020 ↗ |
CVI Investments, Inc.Strategic | —7.80% of class, as filed | — | 13Gfiled Dec 16, 2022 ↗ |
| See all 21 → | |||
- Bob G. Gower's transaction reports restate only vehicles that traded; the 2026 ownership statement (1.21M) is used instead.
- William H. Chang's transaction reports restate only vehicles that traded; the 2021 ownership statement (721) is used instead.
13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 7, 2026 | Bob G. Gower | director | +400,000 | $0.4950 |
| Apr 23, 2026 | Bob G. Gower | director | +508,614 | $0.4840 |
Peers
- Collegium Pharmaceutical
Direct rival in extended-release, abuse-deterrent opioid pain care.
- Vertex Pharmaceuticals
Oral non-opioid acute-pain option with major commercial traction.
- Heron Therapeutics
Postoperative non-opioid analgesia that can displace opioid use.
- Teva (ADR)
Generic extended-release oxycodone alternative for severe pain.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Ensysce Biosciences | $0.3861 | −1.66% | $6.0M | — | — | 5.2 | −15.1% |
| Collegium Pharmaceutical | $24.62 | −2.88% | $798.2M | 19.8 | 3.5 | 1.0 | +6.3% |
| Vertex Pharmaceuticals | $544.44 | −0.04% | $138.20B | 31.7 | 27.8 | 10.9 | +12.5% |
| Heron Therapeutics | $0.3200 | +1.07% | $60.2M | — | — | 0.4 | +1.3% |
| Teva (ADR) | $36.32 | +0.73% | $41.99B | 60.1 | 12.8 | 2.4 | −0.8% |
| Median | 31.7 | 12.8 | 1.7 | +3.8% |